Mainstay Medical starts commercialization of ReActiv8® for the treatment of Chronic Low Back Pain

Dublin, Ireland: 1 February 2017 - Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain, today announces the first sale and implant of ReActiv8 in Germany.

The ReActiv8 implant was performed by Dr med Francis Kilian, Orthopedic and Neurosurgeon at the Catholic Hospital Koblenz-Montabaur in Koblenz Germany.

More info on Mainstay Medical's website.


Next > Confo Therapeutics is awarded € 2.6 million in non-dilutive funding for the discovery of new fibrosis treatments and for expanding the use of its unique Confo® technology

Previous > Green Biologics acquires GreenFlame™ Brand, Inks Kroger as first retail partner for sustainable charcoal lighter fluid